RISE, STABILIZE AND THRIVE
DEAD

Serial Number

98689783

Owner

Cinimod Services, LLC

Attorney

Katharyn Bond

Filing Date

Aug 8, 2024

Add to watchlist:

No watchlists yet
View on USPTO

RISE, STABILIZE AND THRIVE Trademark

Serial Number: 98689783

RISE, STABILIZE AND THRIVE is a trademark filed by Cinimod Services, LLC on August 8, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Cinimod Services, LLC (6 trademarks)

2254 E Mountain St.
Pasadena, CA 91104

Entity Type: 16

Trademark Details

Filing Date

August 8, 2024

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for the treatment of addiction to and abuse of alcohol, opiates, narcotics, food, sex, gambling, and other addictive or habit forming substances or behavior, for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, obesity disease, diabetes disease, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of a subcutaneous drug delivery device sold filled with sustainable release pharmaceutical preparations used in the treatment of addiction to and abuse of alcohol, opiates, narcotics, food, sex, gambling, and other addictive or habit forming substances or behavior, central nervous disorders and other serious and life-threatening diseases, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, obesity disease, diabetes disease, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; pharmaceuticals, namely, implantable drug delivery system comprised of a subcutaneous drug delivery device sold filled with a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction and diabetes disease; pharmaceuticals, namely, implantable drug delivery system comprised of a subcutaneous drug delivery device sold filled with a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening disease; Vitamins; Collagen for medical purposes; Hormone replacement therapy preparations

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Oct 14, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 14, 2025 ABN2
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 27, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 27, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 28, 2025 GNRN
NON-FINAL ACTION E-MAILED
Mar 28, 2025 GNRT
NON-FINAL ACTION WRITTEN
Mar 28, 2025 CNRT
ASSIGNED TO EXAMINER
Feb 24, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 23, 2025 NWOS
NEW APPLICATION ENTERED
Aug 12, 2024 NWAP